Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CUE |
---|---|---|
09:32 ET | 22554 | 0.4502 |
09:34 ET | 13898 | 0.465 |
09:36 ET | 25430 | 0.465 |
09:38 ET | 43392 | 0.485 |
09:39 ET | 13051 | 0.499 |
09:41 ET | 45890 | 0.5666 |
09:43 ET | 50941 | 0.524 |
09:45 ET | 15948 | 0.52115 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cue Biopharma Inc | 22.1M | -0.5x | --- |
Evogene Ltd | 12.8M | -0.6x | --- |
Palatin Technologies Inc | 15.3M | -0.4x | --- |
COSCIENS Biopharma Inc | 15.9M | -0.4x | --- |
Correlate Energy Corp | 22.1M | -0.7x | --- |
Kineta Inc | 7.4M | -0.3x | --- |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.1M |
---|---|
Revenue (TTM) | $8.3M |
Shares Outstanding | 48.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.94 |
EPS | $-0.97 |
Book Value | $0.79 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 2.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -582.23% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.